Ryght and Lucem Health partner to advance disease detection and treatment with AI

Healthcare technology firms Lucem Health and Ryght have joined forces to utilise Ryght's advanced GenAI technology, which employs large language models fine-tuned for the healthcare sector. Lucem Health plans to leverage this technology to extract valuable insights from longitudinal patient records, fostering a deeper understanding of the experiences of patients living with various diseases. Ryght's GenAI platform, designed to ensure compliance with data security standards in the biopharma industry, is expected to contribute to improved patient outcomes, cost reduction, enhanced quality of care, and increased patient satisfaction through its collaboration with Lucem Health.

Simon Arkell, CEO of Ryght, expressed enthusiasm for the collaboration, highlighting Lucem Health's leadership in delivering early disease detection and treatment acceleration solutions. The joint effort aims to enhance Lucem Health's AI SolutionOps platform, already equipped with robust clinical AI capabilities, by incorporating Ryght's innovative copilots and applications. Sean Cassidy, CEO of Lucem Health, emphasised the alignment of Ryght's cutting-edge technology with their vision of transforming healthcare data into actionable insights, enabling clinicians to practise proactive care and achieve better patient outcomes.

Ryght, a privately held healthcare technology company based in Laguna Beach, California, focuses on developing secure generative artificial intelligence (GenAI) solutions for the biopharma industry. Lucem Health specialises in using practical, responsible AI to help healthcare providers accelerate disease detection and treatment, thereby improving patient lives and maximising the clinical and financial yield from limited care delivery resources. The collaboration between these two companies represents a strategic move to harness advanced AI technologies for the benefit of healthcare professionals and patients alike.